SCIENTIFIC REPORTS. (a) NeoGenesis will keep and maintain adequate records containing laboratory data generated in the course of the Program to enable it to furnish complete and accurate information to Mitsubishi regarding the Program activities and results, including all Candidate Compound A, Candidate Compound B and NeoMorph Focused Libraries identified in the Program and all Program Intellectual Property developed by NeoGenesis during the Program. All such written records of NeoGenesis shall be open to inspection by Mitsubishi during normal business hours upon reasonable prior written notice. (b) NeoGenesis shall provide Mitsubishi with reasonably-detailed written reports describing the results of the research performed pursuant to the Program including all Candidate Compound A, Candidate Compound B and NeoMorph Focused Libraries identified in the Program. Such reports shall be delivered to Mitsubishi at least monthly during the Program. NeoGenesis will deliver a Final Target Report (as defined in ATTACHMENT A) with respect to the Program work performed on each Target including a description of all the Candidate Compound A, Candidate Compound B and NeoMorph Sublibraries identified during the Program with respect to such Target.
Appears in 2 contracts
Samples: Service Agreement (Neogenesis Pharmaceuticals Inc), Confidentiality Agreement (Neogenesis Pharmaceuticals Inc)
SCIENTIFIC REPORTS. (a) NeoGenesis will keep and maintain adequate records containing laboratory data generated in the course of the Program to enable it to furnish complete and accurate information to Mitsubishi OGS regarding the Program activities and results, including all Candidate Compound APreliminary Compounds, Candidate Compound B Active Compounds and NeoMorph Focused Libraries identified in the Program and all Program Intellectual Property developed by NeoGenesis during the Program. All such written records of NeoGenesis shall be open to inspection by Mitsubishi OGS during normal business hours upon reasonable prior written notice.
(b) NeoGenesis shall provide Mitsubishi OGS with reasonably-detailed written reports describing the results of the research performed pursuant to the Program including all Candidate Compound APreliminary Compounds, Candidate Compound B Active Compounds and NeoMorph Focused Libraries identified in the Program. Such reports shall be delivered to Mitsubishi OGS at least monthly during the Program. NeoGenesis will deliver a Final Target Report (as defined in ATTACHMENT A) with respect to the Program work performed on each Target including a description of all the Candidate Compound APreliminary Compounds, Candidate Compound B Primary Active Compounds and NeoMorph Sublibraries identified during the Program with respect to such Target.
Appears in 2 contracts
Samples: Screening and Analysis Services Agreement (Neogenesis Pharmaceuticals Inc), Confidential Treatment Agreement (Neogenesis Pharmaceuticals Inc)
SCIENTIFIC REPORTS. (a) NeoGenesis will keep and maintain adequate records containing laboratory data generated in the course of the Program to enable it to furnish complete and accurate information to Mitsubishi OGS regarding the Program activities and results, including all Candidate Compound APreliminary Compounds, Candidate Compound B Active Compounds and NeoMorph Focused Libraries identified in the Program and all Program Intellectual Property developed by NeoGenesis during the Program. All such written records of NeoGenesis shall be open to inspection by Mitsubishi OGS during normal business hours upon reasonable prior written notice.
(b) NeoGenesis shall provide Mitsubishi OGS with reasonably-detailed written reports describing the results of the research performed pursuant to the Program including all Candidate Compound APreliminary Compounds, Candidate Compound B Active Compounds and NeoMorph Focused Libraries identified in the Program. Such reports shall be delivered to Mitsubishi OGS at least monthly during the Program. NeoGenesis will deliver a Final Target Report (as defined in ATTACHMENT Attachment A) with respect to the Program work performed on each Target including a description of all the Candidate Compound APreliminary Compounds, Candidate Compound B Primary Active Compounds and NeoMorph Sublibraries identified during the Program with respect to such Target.
Appears in 1 contract
Samples: License Agreement (Iaso Pharma Inc)